Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

ABSTRACT:

Objective

To test blood and CSF neurofilament light chain (NfL) levels in relation to disease progression and survival in amyotrophic lateral sclerosis (ALS).

Methods

Using an electrochemiluminescence immunoassay, NfL levels were measured in samples from 2 cohorts of patients with sporadic ALS and healthy controls, recruited in London (ALS/control, plasma: n = 103/42) and Oxford (ALS/control, serum: n = 64/36; paired CSF: n = 38/20). NfL levels in patients were measured at regular intervals for up to 3 years. Change in ALS Functional Rating Scale-Revised score was used to assess disease progression. Survival was evaluated using Cox regression and Kaplan-Meier analysis.

Results

CSF, serum, and plasma NfL discriminated patients with ALS from healthy controls with high s

SUBMITTER: Lu CH 

PROVIDER: S-EPMC4456658 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature